Combination Therapy with Chemotherapy, Donor Lymphocyte Infusion with Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia

Ho Jung Choi, Jung Yoon Choi, Bo Kyung Kim, Hong Yul An, Kyung Taek Hong, Hee Young Shin, Hyoung Jin Kang

Research output: Contribution to journalArticle

Abstract

The therapeutic approach for relapsed/refractory acute lymphoblastic leukemia (ALL) remains to be a challenge. The patient was diagnosed as B-cell ALL at 6 months of age and relapsed for the second time following repeat allogeneic hematopoietic stem cell transplantation (one after first complete remission [CR1] and the other after CR2). During blinatumomab monotherapy, he developed an extramedullary relapse. Finally, the combined therapy with clofarabine, donor lymphocyte infusion, and blinatumomab induced CR of the bone marrow and extramedullary relapse. Unfortunately, the patient developed central nervous system relapse, however, this case showed a promising potential for combination therapy with clofarabine, donor lymphocyte infusion, and blinatumomab in relapsed/refractory B-cell ALL.

Original languageEnglish
Article number32251153
JournalJournal of Pediatric Hematology/Oncology
DOIs
StateAccepted/In press - 2020

Keywords

  • blinatumomab
  • childhood
  • donor lymphocyte infusion
  • relapsed/refractory acute lymphoblastic leukemia

Fingerprint Dive into the research topics of 'Combination Therapy with Chemotherapy, Donor Lymphocyte Infusion with Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia'. Together they form a unique fingerprint.

  • Cite this